Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01551498 · ClinicalTrials.gov registry record · Phase 2

Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)

A Phase 2 study, sponsored by Rock Creek Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
165
Enrollment target

NCT01551498: Completed Phase 2 study, sponsored by Rock Creek Pharmaceuticals.

NCT01551498 is a Phase 2 study that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01551498, a Phase 2 study, has completed, sponsored by Rock Creek Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
165 participants
Enrollment target

Study Summary

This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.

Primary Outcome

Collected data on the numbers and types of any adverse effects related to the use of Anatabloc by subjects

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Anatabloc Supplement

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2012-03
Est. Completion 2013-02
Phase Phase 2
Rock Creek Pharmaceuticals

5 total trials

What the finished NCT01551498 record still lists

NCT01551498 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01551498 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01551498 about?

NCT01551498 is a clinical study titled "Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)". This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.

What is the current status of trial NCT01551498?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2012-03. Estimated completion is 2013-02.

What interventions are being tested in trial NCT01551498?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Anatabloc Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01551498?

This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01551498's enrollment target sits among peer trials

165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01551498, the US trial registry maintained by the National Library of Medicine. NCT01551498 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.